Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imeglimin in Diabetes With Liver Cirrhosis
jRCT1031240269Recruiting
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of imeglimin in hepatogenous diabetes (HD) and type 2 diabetes mellitus (T2DM). Primary endpoint: Indicators of blood glucose variability before and after imeglimin administration. Started Aug 2024; status: recruiting.
02
Drugs
imeglimin
03
Conditions
hepatogenous diabetes (HD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT1031240269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031240269.